Key Sessions

Jim Sesic

Navigating the Global Regulatory Landscape for Cell and Gene Therapies

Atara Biotherapeutics

Daniel Getts

Case Study: In Vivo CAR-T Therapies Development, Clinical Advances and Scale Up Strategies

CREATE Medicines

Wednesday April 29th 2026 - Day 2Wednesday, 29 April 2026 - CT (China Time, GMT+08:00)

08:30 - 09:00

Registration

09:00 - 09:10

Chairperson's Opening Remarks

In Vivo Cell Therapy Development, Manufacturing and Clinical Advances

Showing 1 of 1 Streams

Cell & Gene Therapy Summit

09:10 - 09:40

Case Study: In Vivo CAR-T Therapies Development, Clinical Advances and Scale Up Strategies

Daniel Getts - CEO, CREATE Medicines

09:40 - 10:10

Optimising LNP Delivery Platforms and Application for In Vivo Cell Therapies

Development of robust LNP delivery systems
Optimising LNP engineering to minimize off site delivery
Overcoming scalability and reproducibility challenges
Critical parameters influencing LNP manufacturing efficiency, consistency, and scalability
Optimising LNP formulation design
Analytical control strategy for LNPs
Manufacturing innovation: Reducing cold-chain dependence & improving temperature stability
Supply chain considerations for commercial viability
Case Study: Successful LNP Scale-Up and steps towards in vivo cell therapies

10:10 - 10:40

Sponsored Scientific Track Presentation

Spotlight Presentation – Calling all Technology Thought Leaders!

Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.

10:40 - 11:10

Morning Coffee and Networking Break in Exhibition Hall

R&D Innovations – New Modalities, Solid Tumours and Larger Patient Populations

Showing 1 of 1 Streams

Cell & Gene Therapy Summit

11:10 - 11:40

Achieving Potent and Long-Term Persistence of Allogeneic CAR-T Cells through Glycosylation Manipulation

A single gene Knock-out SPPL3 deletion remodels glycosylation in primary T cells, suppressing TCR-driven alloreactivity and host rejection while preserving anti-CD19 CAR-T effector function against tumours. In a Phase I investigator-initiated trial (IIT) involving B-NHL patients, this glycan-shielded approach demonstrated safety and durable persistence with potent tumour control. Preclinical proof of concept was also successfully established for solid tumour applications.

Feifei Liang - Senior Vice President/R&D leader, EdiGene Inc.

11:40 - 12:10

Beyond CAR-T: Reprogramming Myeloid Cells to Conquer Solid Tumors – The Signadori Bio Case Study

As the limitations of CAR-T therapies in solid tumors become increasingly evident, a new wave of innovation is emerging from the myeloid cell compartment. This session spotlights Signadori Bio, a Sofinnova-backed biotech born from a strategic partnership with Gustave Roussy, Europe’s leading cancer center. The company is pioneering a gene-modified monocyte-derived macrophage in vivo platform designed to remodel the tumor microenvironment and overcome resistance mechanisms in solid cancers. Attendees will gain insight into the scientific rationale, translational strategy, and in vivo delivery roadmap behind Signadori Bio’s lead program. This case study offers a compelling look at how next-generation in vivo platforms are being built from the ground up to address the unmet needs in oncology.

Matthieu Coutet - Partner, Sofinnova

12:10 - 12:40

What's the Next for TIL Biology and Engineering?

Hequn Yin - Former SVP of Iovance and Head of Research, Iovance Biotherapeutics

12:40 - 13:10